# Immutep Limited (IMMP) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/IMMP
## Company Profile
- Ticker: IMMP
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Australia and listed in the U
- Tags: Immunotherapy, Oncology, Immunology
## Stock Data
- Close: 0.3649 USD
- Market cap: 61306806.496 USD
- Last updated: 2026-09-04
## Business Overview
Immutep is a biotechnology company focused on immunotherapy and checkpoint modulation, with programs in cancer and immune disease. Its story is built around developing differentiated immune therapies that can complement existing oncology treatments.
## Why The Stock Is Moving

As of Sep 4, 2026, IMMP was little changed and closed at $0.3649. No new same-company headline was identified in the current news window.

## Geographic Base

Immutep is headquartered in Australia and listed in the U.S. market. It sits in small-cap oncology biotechnology.

## Business Model

The company depends on clinical readouts, translational validation, and the ability to maintain a narrow immunotherapy pipeline. Investors usually watch efficacy signals and strategic collaborations.

## Landscape Position

Immutep occupies a specialized immuno-oncology niche within biotech. The stock is catalyst-sensitive because the platform still needs to prove broad clinical relevance.

## Future Catalysts

- Immutep’s catalysts are eftilagimod alfa and the immuno-oncology program, where the next update can significantly shift sentiment. The company still needs human proof.

## Recent News
- 2026-07-30 12:00 EST — [Immutep Quarterly Activities Report Q4 FY26](https://biopharmsignal.com/news/IMMP/immutep-quarterly-activities-report-q4-fy26-813a9fec) — Source: Immutep Limited
- 2026-07-24 12:00 EST — [Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026](https://biopharmsignal.com/news/IMMP/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-e824d073) — Source: Immutep Limited
- 2026-07-14 12:00 EST — [Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor](https://biopharmsignal.com/news/IMMP/immutep-secures-fourth-united-states-patent-for-eftilagimod-alfa-in-combination--eee3de23) — Source: Immutep Limited
- 2026-07-13 12:00 EST — [Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004](https://biopharmsignal.com/news/IMMP/immutep-provides-clinical-update-in-1st-line-nsclc-positive-mature-overall-survi-62ccc2c6) — Source: Immutep Limited
- 2026-06-04 12:00 EST — [Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026](https://biopharmsignal.com/news/IMMP/immutep-to-present-positive-interim-phase-i-data-for-imp761-a-first-in-class-lag-b9b47442) — Source: Immutep Limited